TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26947201

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab 1600 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intravenous rituximab 500 mg/m(2)
Number of subjects: 176
Study: 24355665

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination through school-located vaccination program (SLV-I)
Number of subjects: 0
Study: 22674243

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 4 ml 1% procaine HCl
Number of subjects: 57

Group type: COMPARATOR
Intervention: 1 ml 0.09% saline (placebo)
Number of subjects: 57
Study: 19171400

Group type: EXPERIMENTAL
Intervention: High serum apoA-I levels (top tertile)
Number of subjects: 2111

Group type: COMPARATOR
Intervention: Low serum apoA-I levels (bottom tertile)
Number of subjects: 2111
Study: 18637956

Group type: EXPERIMENTAL
Intervention: Contralateral transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard exploration training (Control)
Number of subjects: 3
Study: 16719158

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: No rGH treatment (Control Group)
Number of subjects: 18
Study: 12534607

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate mousse (BVM) applied twice daily for 4 weeks
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard therapies (ST) applied once or twice daily for 4 weeks
Number of subjects: 241
Study: 11067784

Group type: EXPERIMENTAL
Intervention: White blood cell count 0 to 5x10(9)/L
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: White blood cell count 5 to 10x10(9)/L
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: White blood cell count 10 to 15x10(9)/L
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: White blood cell count >15x10(9)/L
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Higher WBC count
Number of subjects: 975
Study: 8860884

Group type: EXPERIMENTAL
Intervention: 300 mg daily oral progesterone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 200 mg daily vaginal progesterone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 25
Study: 1292916

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg, b.i.d.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midecamycin acetate (600 mg, b.i.d.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6430768

Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (isosorbide dinitrate) acute administration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (isosorbide dinitrate) long-term treatment (40 mg four times daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingually-administered nitroglycerin (GTN)
Number of subjects: 11
Study: 31610718

Group type: EXPERIMENTAL
Intervention: Antiplatelet use
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Continued warfarin
Number of subjects: 1343
Study: 29696423

Group type: EXPERIMENTAL
Intervention: Patterns of interactions among patients, caregivers, and healthcare providers during symptom discussions
Number of subjects: 37
Study: 26292778

Group type: COMPARATOR
Intervention: 6 SQ-HDM
Number of subjects: 992

Group type: COMPARATOR
Intervention: 12 SQ-HDM
Number of subjects: 992
Study: 24911223

Group type: EXPERIMENTAL
Intervention: Forgiveness group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: General group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 22227159

Group type: EXPERIMENTAL
Intervention: High-low mixture group (high training accuracy mixed with low training accuracy, no feedback)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-low mixture group (low training accuracy mixed with low training accuracy, no feedback)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High accuracy training without feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: High and low accuracy training mixed with feedback
Number of subjects: 36
Study: 19106238

Group type: EXPERIMENTAL
Intervention: 200 g/d of a dairy drink with 5.8 mg IPP and 4.4 mg VPP
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 100 g/d of a dairy drink with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added K
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: LTPs and potassium
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: LTPs alone
Number of subjects: 162
Study: 17508235

Group type: EXPERIMENTAL
Intervention: TACE using high-kilovoltage (120-kV) DSA and fluoroscopy modes (group B; n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: TACE using standard-kilovoltage (75- to 90-kV) DSA and fluoroscopy modes (group A; n = 20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 43
Study: 15834843

Group type: COMPARATOR
Intervention: Nabilone (2 mg/day)
Number of subjects: 6
Study: 12075250

Group type: EXPERIMENTAL
Intervention: Enoxaparin during the acute phase
Number of subjects: 1218

Group type: COMPARATOR
Intervention: TIMI risk score for UA/NSTEMI
Number of subjects: 1218
Study: 9583393

Group type: EXPERIMENTAL
Intervention: Intravenous line placement with intradermal saline + benzyl alcohol (0.9%)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravenous line placement with intradermal lidocaine (1%)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 99
Study: 7703876

Group type: EXPERIMENTAL
Intervention: Early discharge program (hospital stay less than 60 hours plus home follow-up by hospital-based nurses)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional hospital care (hospital stay more than 60 hours and no home follow-up by hospital staff)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Transferred to early discharge (originally assigned to traditional care)
Number of subjects: 81
Study: 2203253

Group type: EXPERIMENTAL
Intervention: 180 mg beta-carotene/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous photosensitivity-prevention studies
Number of subjects: 0
Study: 938116

Group type: EXPERIMENTAL
Intervention: Supine position throughout the operative procedure (Group I)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Change to a 15 degrees head down position 15 minutes after a control blood sample (Group II)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic abdominal laparotomy pack without a change in operative position
Number of subjects: 64
Study: 30833297

Group type: EXPERIMENTAL
Intervention: Unhealthy snacks (viewed influencers with unhealthy snacks)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Nonfood products (viewed influencers with nonfood products)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Healthy snacks (viewed influencers with healthy snacks)
Number of subjects: 176
Study: 28683834

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer of US$84 per month for 5 months
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Single non-food items kit
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Free piped water
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (not receiving the intervention)
Number of subjects: 1200
Study: 25450123

Group type: EXPERIMENTAL
Intervention: Combined training of progressive muscle relaxation, mental imagery, and phantom exercises 2 times/wk for 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical therapy dedicated to the residual limb
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined training of progressive muscle relaxation, mental imagery, and phantom exercises
Number of subjects: 51
Study: 22880843

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1286
Study: 21493732

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 + 10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 32
Study: 18650512

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 17120844

Group type: EXPERIMENTAL
Intervention: Modal completion display
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amodal completion display
Number of subjects: 32
Study: 12433644

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microgram/3ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 30
Study: 10328392

Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet concentrate (APC) during surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standardized macular hole surgery without APC
Number of subjects: 110
Study: 8598374

Group type: EXPERIMENTAL
Intervention: Monitored group (online observation and intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unmonitored group (imaged but not monitored)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unmonitored group
Number of subjects: 32
Study: 2046369

Group type: EXPERIMENTAL
Intervention: Regular alcohol content beer (7% alcohol by volume)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (3% alcohol)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Mixed drinks made with 7/8-oz of distilled spirits
Number of subjects: 318

Group type: COMPARATOR
Intervention: Low-alcohol conditions (3% beer or mixed drinks)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Females drinking at the same rate as males
Number of subjects: 318
Study: 6888028

Group type: EXPERIMENTAL
Intervention: 35-minute tutorial on how to conduct a discharge interview; n = 181
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: 15-minute discharge interview from an investigator; n = 53
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Both interventions (35-minute tutorial and 15-minute discharge interview); n = 63
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group; n = 248
Number of subjects: 545
Study: 31477163

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary diabetes mellitus care with patient empowerment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study: 27896711

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TOCAS monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26271567

Group type: EXPERIMENTAL
Intervention: Pathogenetic therapy with antihypoxant reamberin (N=64)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Pathogenetic therapy with antihypoxant reamberin and hepatoprotector remaxol (N=84)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nutritional support and laparoscopic abdominal sanitation (part of both intervention groups)
Number of subjects: 232
Study: 24357857

Group type: EXPERIMENTAL
Intervention: 0.2% cetrimide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 26
Study: 23000015

Group type: EXPERIMENTAL
Intervention: RUN task
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EDIT task
Number of subjects: 48

Group type: COMPARATOR
Intervention: RT task (control)
Number of subjects: 48
Study: 19188252

Group type: EXPERIMENTAL
Intervention: Rapamycin treatment prior to exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no rapamycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 17286194

Group type: EXPERIMENTAL
Intervention: Preoperative informative video
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 100
Study: 15530681

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Influenza and pneumococcal vaccine
Number of subjects: 39
Study: 11586492

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day, n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study: 9451630

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REx)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 16
Study: 8572850

Group type: EXPERIMENTAL
Intervention: Indapamide IR 2.5 mg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Indapamide SR 2.0 mg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Indapamide SR 2.5 mg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 2500368

Group type: EXPERIMENTAL
Intervention: Semipermanent vascular access catheters (VACs) maintained without occlusive dressings, antibiotics, repeated flushings or heparin.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Semipermanent vascular access catheters (VACs)
Number of subjects: 26
Study: 966146

Group type: EXPERIMENTAL
Intervention: Orally administered methotrimeprazine
Number of subjects: 13
Study: 31218230

Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer Diabetes (GET.ON M.E.D.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Online psychoeducation control group
Number of subjects: 40
Study: 28017546

Group type: EXPERIMENTAL
Intervention: 1% prilocaine (Xylonaest) in combination with epinephrine 1:100,000
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ropivacaine (10 mg Naropin, 5 ml sodium chloride, 1 ml epinephrine)
Number of subjects: 31
Study: 26016467

Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 100
Study: 23295794

Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg once every 90 days)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (temozolomide or dacarbazine)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 655

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy
Number of subjects: 655
Study: 21332467

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1582
Study: 19762088

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2mg/kg every 6h) with nebulized L-epinephrine (0.5mg/kg every 4h)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2mg/kg every 6h) without nebulized L-epinephrine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control groups received nebulized or intravenous isotonic saline solution, or both
Number of subjects: 64
Study: 16913269

Group type: EXPERIMENTAL
Intervention: H1-antihistamine (loratadine) + intranasal glucocorticosteroid (mometasone furoate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intranasal glucocorticosteroid (mometasone furoate) alone
Number of subjects: 24
Study: 15605620

Group type: EXPERIMENTAL
Intervention: Hypericum extract STW 3-VI 900 mg once daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 11771826

Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MgSO4 and GIK infusion after 10 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no infusates)
Number of subjects: 20
Study: 9027913

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Antimalarial chemoprophylaxis in primigravidae
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Balanced protein/energy supplementation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Zinc supplementation during gestation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Folate supplementation during gestation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation during gestation
Number of subjects: 126
Study: 8098059

Group type: EXPERIMENTAL
Intervention: Taxotere 6-hour infusion at a maximally tolerated dose of 100 mg/m2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Taxotere 2-hour infusion at a maximally tolerated dose of 115 mg/m2
Number of subjects: 58
Study: 3419825

Group type: EXPERIMENTAL
Intervention: Sheedy Disparometer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mallett test
Number of subjects: 22
Study: 30544179

Group type: EXPERIMENTAL
Intervention: Spirited Life wellness intervention including a 10-week online weight-loss program and monthly health coaching for 24 months
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Spirited Life wellness intervention
Number of subjects: 719
Study: 30624670

Group type: EXPERIMENTAL
Intervention: Vitamin D 3 12,000 IU
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Vitamin D 3 24,000 IU
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Vitamin D 3 48,000 IU
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 379
Study: 25384514

Group type: EXPERIMENTAL
Intervention: High repetition/low load resistance training (HR/LL‐RT) program, 3 sets of 20 repetitions, two times a week, initial load at 30% of 1-RM for 8 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 20
Study: 22992330

Group type: EXPERIMENTAL
Intervention: Intensive computerized auditory training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Set-based analysis of 42 SNPs in the COMT gene
Number of subjects: 48
Study: 21706145

Group type: EXPERIMENTAL
Intervention: romiplostim (3 μg/kg weekly for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 34
Study: 17453342

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 5 years
Number of subjects: 357

Group type: COMPARATOR
Intervention: Tamoxifen treatment for 2 years
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: High HOXB13:IL17BR ratio
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: High HOXB13 expression
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: IL17BR in systemically untreated cohort
Number of subjects: 357
Study: 21615813

Group type: EXPERIMENTAL
Intervention: Recent coronary revascularization (CR) [<2 years]
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Nonrecent coronary revascularization (CR) [≥2 years]
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: No coronary revascularization (CR)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Time from CR as a continuous measure
Number of subjects: 720
Study: 16272186

Group type: EXPERIMENTAL
Intervention: MDMA 75mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methylphenidate 20mg
Number of subjects: 18
Study: 11823690

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU), 600 mg/m2 (arm I)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 intravenous bolus and interferon-alpha, 5 MU subcutaneously, three times a week (arm II)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Leucovorin 200 mg/m2 in 2-hour infusion and 5-FU 500 mg/m2 intravenous bolus (arm III)
Number of subjects: 192
Study: 9696232

Group type: EXPERIMENTAL
Intervention: Mixed immunobeads screen
Number of subjects: 9

Group type: COMPARATOR
Intervention: SpermMar
Number of subjects: 9

Group type: COMPARATOR
Intervention: Immunobead test
Number of subjects: 9
Study: 8556745

Group type: EXPERIMENTAL
Intervention: Modified toothpaste technique (instructions on spreading paste, limiting expectoration, filtering foam, no rinsing, no eating/drinking for 2 hours)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (no specific instructions on toothpaste use or rinsing)
Number of subjects: 369
Study: 2707464

Group type: EXPERIMENTAL
Intervention: Human follicular fluid (FF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Heat-inactivated human follicular fluid (FF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ham's F‐10 medium (control)
Number of subjects: 31
Study: 588393

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diethyl ether
Number of subjects: 20
Study: 171161

Group type: EXPERIMENTAL
Intervention: Intragastric fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Number of subjects: 0
Study: 30887723

Group type: EXPERIMENTAL
Intervention: Caveolin-1 slow-release material
Number of subjects: 72
Study: 29549378

Group type: EXPERIMENTAL
Intervention: Randomized Dichotic Digits Test and Dichotic Words Test
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Clinical Evaluation of Language Fundamentals (CELF)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Dichotic listening tests
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: CELF
Number of subjects: 782
Study: 27350217

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25197737

Group type: EXPERIMENTAL
Intervention: Game-based oral health education (snakes and ladders game combined with flash cards)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional oral health education (flash cards once daily for 7 days)
Number of subjects: 120
Study: 22676409

Group type: COMPARATOR
Intervention: Education intervention consisting of a 45-minute session on effective telephone referrals, including discussion, video critique, ISBAR practice, and provision of a memory aid.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (pre-intervention recordings)
Number of subjects: 160
Study: 21436928

Group type: EXPERIMENTAL
Intervention: Elective pharmacy course in anticoagulation management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 'Living with anticoagulation' assignment
Number of subjects: 0